$14.27
2.15% today
Nasdaq, Oct 03, 03:48 pm CET

Integra LifeSciences Holdings Corporation Stock price

$13.97
-1.19 7.85% 1M
-7.81 35.86% 6M
-8.71 38.40% YTD
-3.35 19.34% 1Y
-29.87 68.13% 3Y
-33.26 70.42% 5Y
-16.56 54.23% 10Y
-3.29 19.08% 20Y
Nasdaq, Closing price Thu, Oct 02 2025
-0.76 5.16%

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$2.7b
Net debt
$1.6b
Cash
$253.6m
Shares outstanding
77.9m
Valuation (TTM | estimate)
P/E
negative | 6.2
P/S
0.7 | 0.6
EV/Sales
1.7 | 1.6
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
38.3%
Return on Equity
-0.5%
ROCE
5.6%
ROIC
4.2%
Debt/Equity
1.8
Financials (TTM | estimate)
Revenue
$1.6b | $1.7b
EBITDA
$168.4m | $335.3m
EBIT
$153.5m | $276.5m
Net Income
$-500.6m | $175.8m
Free Cash Flow
$-47.4m
Growth (TTM | estimate)
Revenue
3.5% | 5.7%
EBITDA
-33.8% | 70.4%
EBIT
-36.5% | 51.4%
Net Income
-2,216.8% | 2,633.7%
Free Cash Flow
-180.3%
Margin (TTM | estimate)
Gross
57.2%
EBITDA
10.4% | 19.7%
EBIT
9.5%
Net
-30.9% | 10.3%
Free Cash Flow
-2.9%
More
EPS
$-6.5
FCF per Share
$-0.6
Short interest
13.4%
Employees
4k
Rev per Employee
$370.0k
Show more

Is Integra LifeSciences Holdings Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Integra LifeSciences Holdings Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

3x Buy
18%
7x Hold
41%
7x Sell
41%

Analyst Opinions

17 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

Buy
18%
Hold
41%
Sell
41%

Financial data from Integra LifeSciences Holdings Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,622 1,622
4% 4%
100%
- Direct Costs 694 694
15% 15%
43%
928 928
4% 4%
57%
- Selling and Administrative Expenses 668 668
7% 7%
41%
- Research and Development Expense 92 92
7% 7%
6%
168 168
34% 34%
10%
- Depreciation and Amortization 15 15
15% 15%
1%
EBIT (Operating Income) EBIT 153 153
36% 36%
9%
Net Profit -501 -501
2,217% 2,217%
-31%

In millions USD.

Don't miss a Thing! We will send you all news about Integra LifeSciences Holdings Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Integra LifeSciences Holdings Corporation Stock News

Neutral
GlobeNewsWire
11 days ago
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.
Positive
Seeking Alpha
23 days ago
Integra LifeSciences remains deeply discounted due to ongoing operational setbacks, with the market adopting a cautious 'show me' stance until clear improvements emerge. Remediation and margin improvement plans are underway, but shipping holds and tariffs continue to pressure revenue and profitability, delaying a full recovery until at least 2026. Core businesses, including higher-value wound c...
Neutral
Seeking Alpha
23 days ago
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Good morning, everyone, and welcom...
More Integra LifeSciences Holdings Corporation News

Company Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Head office United States
CEO Mojdeh Poul
Employees 4,396
Founded 1989
Website www.integralife.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today